Telix Pharmaceuticals Ltd（TLX）の株式分析TLXTelix Pharmaceuticals Ltd

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx. It operates in the Healthcare sector.

Telix Pharmaceuticals is currently a hold. The stock closed at $11.29, which is below the analyst price target of $22 from Citi, indicating potential upside. However, the RSI is at 42.57, suggesting it is nearing oversold territory, and the forward P/E ratio is high at 156.25, indicating the stock may be overvalued. The main risk is the downgrade from RBC Capital, which reflects concerns about valuation despite strong revenue growth.